Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients with Male Androgenic Alopecia in South Korea: A Multicentre Chart Review Study
3
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Dutasteride improves hair growth compared with finasteride in maleandrogenic alopecia (AGA) and is well tolerated. However, real-world evidence for longtermdutasteride use in AGA is lacking. Objective: To describe baseline characteristics, treatment patterns and long-term safety andeffectiveness of dutasteride versus finasteride. Methods: This was a multicentre, retrospective medical chart review study conductedin South Korea. The index date was the first prescription of dutasteride or finasteride. Baseline characteristics were assessed 6 months prior to index. Safety and effectiveness(improvements in basic and specific [BASP] classification) data were collected from indexthroughout the observation period. Results: Overall, 600 male adult patients were included (dutasteride, n=295; finasteride,n=305). Dutasteride-treated patients were older (p<0.001) and more likely to have moderate/severe BASP classification at baseline (p=0.010) compared with finasteride-treated patients. Among patients treated with recommended, on-label dosing exclusively (n=535: dutasteride,n=250; finasteride, n=285), dutasteride-treated patients showed greater improvementin hair growth than finasteride-treated patients, as measured by the BASP basic M classification(adjusted incidence rate ratio [95% confidence interval]: 2.06 [1.08, 3.95]; p=0.029). Among this same subset, overall occurrence of adverse events (AEs) during the observationperiod were not statistically equivalent between groups (dutasteride 7.6%, finasteride 10.5%;p=0.201), although reports of AEs of special interest were equivalent (p<0.001). Conclusion: Dutasteride showed greater effectiveness than finasteride in improving BASP classificationin treating male AGA and had a similar or possibly lower occurrence of overall AEs. Dutasteride may provide an effective and safe treatment option for male patients with AGA.
Abstract
Background: Dutasteride improves hair growth compared with finasteride in maleandrogenic alopecia (AGA) and is well tolerated. However, real-world evidence for longtermdutasteride use in AGA is lacking. Objective: To describe baseline characteristics, treatment patterns and long-term safety andeffectiveness of dutasteride versus finasteride. Methods: This was a multicentre, retrospective medical chart review study conductedin South Korea. The index date was the first prescription of dutasteride or finasteride. Baseline characteristics were assessed 6 months prior to index. Safety and effectiveness(improvements in basic and specific [BASP] classification) data were collected from indexthroughout the observation period. Results: Overall, 600 male adult patients were included (dutasteride, n=295; finasteride,n=305). Dutasteride-treated patients were older (p<0.001) and more likely to have moderate/severe BASP classification at baseline (p=0.010) compared with finasteride-treated patients. Among patients treated with recommended, on-label dosing exclusively (n=535: dutasteride,n=250; finasteride, n=285), dutasteride-treated patients showed greater improvementin hair growth than finasteride-treated patients, as measured by the BASP basic M classification(adjusted incidence rate ratio [95% confidence interval]: 2.06 [1.08, 3.95]; p=0.029). Among this same subset, overall occurrence of adverse events (AEs) during the observationperiod were not statistically equivalent between groups (dutasteride 7.6%, finasteride 10.5%;p=0.201), although reports of AEs of special interest were equivalent (p<0.001). Conclusion: Dutasteride showed greater effectiveness than finasteride in improving BASP classificationin treating male AGA and had a similar or possibly lower occurrence of overall AEs. Dutasteride may provide an effective and safe treatment option for male patients with AGA.
참고문헌 (24)
- Kaufman KD, "Androgens and alopecia", Mol Cell Endocrinol, 198, pp.89~95 (2002)
- WolffH, "The diagnosis and treatment of hair and scalp diseases", Dtsch Arztebl Int, 113, pp.377~386 (2016)
- Sung Hyub Han, "Quality of Life Assessment in Male Patients with Androgenetic Alopecia: Result of a Prospective, Multicenter Study", Annals of Dermatology, 24(3), pp.311~318 (2012), 대한피부과학회[DOI]
- Kanti V, "Evidence-based(S3)guideline for the treatment of androgenetic alopecia in women and in men-short version", J Eur Acad Dermatol Venereol, 32, pp.11~22 (2018)
- Chung HC, "Long-term efficacy and safety of the dual 5-alpha reductase blocker dutasteride on male androgenetic alopecia patients", J Dermatol, 44, pp.1408~1409 (2017)
- Eun HC, "Efficacy, safety, and tolerability of dutasteride 0. 5 mg once daily in male patients with male pattern hair loss : a randomized, double-blind, placebo-controlled, phase III study", J Am Acad Dermatol, 63, pp.252~258 (2010)
- Gubelin Harcha W, "A randomized, active-and placebocontrolled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia", J Am Acad Dermatol, 70, pp.489~498 (2014)
- Shanshanwal SJ, "Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia : a randomized controlled open-label, evaluator-blinded study", Indian J Dermatol Venereol Leprol, 83, pp.47~54 (2017)
- Hirshburg JM, "Adverse effects and safety of 5-alpha reductase inhibitors(finasteride, dutasteride) : a systematic review", J Clin Aesthet Dermatol, 9, pp.56~62 (2016)
- Clark RV, "Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor", J Clin Endocrinol Metab, 89, pp.2179~2184 (2004)
- "Avodart Soft Capsule 0.5mg (Dutasteride)" (2004)[URL]
- "Nuvaniv License Details" (2007)[URL]
- "Zagallo Review Report" (2015)[URL]
- Stough D, "Dutasteride improves male pattern hair loss in a randomized study in identical twins", J Cosmet Dermatol, 6, pp.9~13 (2007)
- 최광성, "Safety and Tolerability of the Dual 5-Alpha Reductase Inhibitor Dutasteride in the Treatment of Androgenetic Alopecia", Annals of Dermatology, 28(4), pp.444~450 (2016), 대한피부과학회
- Tsunemi Y, "Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia", J Dermatol, 43, pp.1051~1058 (2016)
- Lee WS, "A new classification of pattern hair loss that is universal for men and women : basic and specific(BASP)classification", J Am Acad Dermatol, 57, pp.37~46 (2007)
- Zhou Z, "The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia : a systematic review and meta-analysis", Clin Interv Aging, 14, pp.399~406 (2019)
- Olsen EA, "The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss : results of a randomized placebocontrolled study of dutasteride versus finasteride", J Am Acad Dermatol, 55, pp.1014~1023 (2006)
- Shin JW, "Evaluation of long-term efficacy of finasteride in Korean men with androgenetic alopecia using the basic and specific classification system", J Dermatol, 46, pp.139~143 (2019)
- Gupta AK, "Efficacy of non-surgical treatments for androgenetic alopecia in men and women : a systematic review with network meta-analyses, and an assessment of evidence quality", J Dermatolog Treat, 33, pp.62~72 (2022)
- Lee S, "Adverse sexual effects of treatment with finasteride or dutasteride for male androgenetic alopecia : a systematic review and meta-analysis", Acta Derm Venereol, 99, pp.12~17 (2019)
- Yeo IK, "An epidemiological study of androgenic alopecia in 3114 Korean patients", Clin Exp Dermatol, 39, pp.25~29 (2014)
- Manabe M, "Guidelines for the diagnosis and treatment of male-pattern and femalepattern hair loss, 2017 version", J Dermatol, 45, pp.1031~1043 (2018)